| gap-pubmed-20260410- | Why does autophagy-null (ATG5 KO) condition paradoxically increase VGF secretion | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the molecular mechanism by which LRRK2-VAMP4/VAMP7 interactions regulate | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does VAMP2 knockout increase VGF secretion while VAMP4/VAMP7 knockout decrea | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the optimal management strategies for specific meningioma patient popul | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What biological mechanisms drive aggressive behavior in the subset of treatment- | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What molecular taxonomy can unify meningioma classification and predict biologic | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What mechanisms link maternal brain structural changes to specific maternal beha | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | behavioral-neuroscience |
| gap-pubmed-20260410- | How do pregnancy hormones causally drive specific neuroanatomical changes in the | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neuroendocrinology |
| gap-pubmed-20260410- | What specific brain plasticity mechanisms underlie MRI-detected structural chang | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroplasticity |
| gap-pubmed-20260410- | What determines whether dysbiosis-induced gut-brain signaling alterations lead t | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do microRNA-mediated epigenetic changes in the gut translate to specific alt | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which microbial metabolites cross | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What drives the female-specific excess of microbleeds in APOE4 carriers independ | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do microbleeds occur predominantly in cortical layers 4-5 while CAA affects | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cerebrovascular-pathology |
| gap-pubmed-20260410- | What mechanism explains how microbleeds precede and potentially seed amyloid pla | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does noradrenergic denervation mechanistically impair olfactory information | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurocircuitry |
| gap-pubmed-20260410- | Why are LC axons in the olfactory bulb selectively vulnerable compared to other | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What signals trigger microglia to specifically recognize and phagocytose LC axon | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does PNS specifically target retinal microglia versus systemic inflammatory | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which specific PNS components cross the blood-retinal barrier and how do their i | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do genetic risk factors for suicide attempt differ mechanistically between a | open | 0.74 | 0.00 | 2026-04-10 | 0 | | psychiatric-genetics |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which the 12 identified genetic lo | open | 0.80 | 0.00 | 2026-04-10 | 0 | | psychiatric-genetics |
| gap-pubmed-20260410- | How can integrated staging schemes account for the variable impact of common cop | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the temporal sequence and mechanistic relationship between amylo | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do cognitive reserve and resistance mechanisms modify the relationship betwe | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What alternative preclinical models could improve the <10% predictive value for | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do immune response differences between rodents and humans contribute to ther | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific mechanisms underlie the species differences in protein aggregation | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do unfavorable microenvironmental factors limit MSC therapeutic efficacy in | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific mechanisms underlie the synergistic effects of multi-gene MSC co-t | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does passive incubation preserve EV integrity better than active loading des | open | 0.77 | 0.00 | 2026-04-10 | 0 | | bioengineering |
| gap-pubmed-20260410- | What mechanisms enable neuropeptide-loaded MSC-EVs to cross the blood-brain barr | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurotherapeutics |
| gap-pubmed-20260410- | Why do MSC-EVs demonstrate superior regenerative effects compared to HEK293-EVs | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroregeneration |
| gap-pubmed-20260410- | How does CHCHD10 dysfunction lead to cristae junction loss and destabilized mito | open | 0.82 | 0.00 | 2026-04-10 | 0 | | mitochondrial-biology |
| gap-pubmed-20260410- | What determines the tissue-specific vulnerability pattern in CHCHD10 mutations ( | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does muscle OXPHOS deficiency mechanistically trigger downstream NMJ fragmen | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do non-energetic mitochondrial functions contribute to ASD beyond impaired A | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | What specific mechanisms link mitochondrial electron transport chain dysfunction | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | What determines the specificity of TFEB-induced signaling endosomes for differen | open | 0.76 | 0.00 | 2026-04-10 | 0 | | cellular-clearance-mechanisms |
| gap-pubmed-20260410- | How does TFEB-mediated endocytosis specifically contribute to neurodegeneration | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do adherence rates and functional trajectories differ between Korean and glo | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the real-world ARIA incidence rates and cognitive outcomes for lecanema | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What functional role does the unique choroid plexus microglial subset play in ce | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do BAM subsets with mixed ontogeny and different self-renewal capacities con | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive the tissue-specific transcriptional signatures o | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why does gene-environment interaction selectively impair D2R-dependent LTD while | open | 0.76 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms explain how prenatal nicotine specifically alters D2R | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopmental-disorders |
| gap-pubmed-20260410- | How does α-ketoglutarate mechanistically drive the observed epigenetic and trans | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does only chronic, but not acute, NLRP3 inhibition reproduce the metabolic a | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the molecular mechanism linking NLRP3 loss to increased Slc1a3 expressio | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |